Pairing obinutuzumab with venetoclax in relapsed CLL

Kerry A. Rogersa Division of Hematology, The Ohio State University, Columbus, OHCorrespondence[email protected]
View further author information

Philip A. Thompsonb Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia;c The Sir Peter MacCallum Department of Clinical Oncology, University of Melbourne, Parkville, AustraliaView further author information

Click to increase image sizeClick to decrease image size

Acknowledgements

KAR is a Scholar in Clinical Research of the Leukemia & Lymphoma Society.

Disclosure statement

KAR receives research funding from Genentech, AbbVie, and Novartis, consults for Genentech, AbbVie, Pharmacyclics, Janssen, AstraZeneca, BeiGene, LOXO@Lilly, and Alpine Immune Sciences. P.A.T. has served as a paid consultant for AbbVie, Adaptive Biotechnologies, Ascentage, AstraZeneca, Beigene, Genentech, Janssen, Lilly, and Merck and received honoraria from AbbVie, Adaptive Biotechnologies, AstraZeneca, Janssen and Merck.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Pairing obinutuzumab with venetoclax in relapsed CLL

Information for

Open access

Opportunities

Help and information

Pairing obinutuzumab with venetoclax in relapsed CLL

Acknowledgements

Disclosure statement

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature